Evaluation of Muscle Mass from Chest CT versus Body Mass Index in Determining Severity and Outcomes in Non-Cystic Fibrosis Bronchiectasis - Report - MDSpire

Evaluation of Muscle Mass from Chest CT versus Body Mass Index in Determining Severity and Outcomes in Non-Cystic Fibrosis Bronchiectasis

  • By

  • Ping-Huai Wang

  • Shih-Lung Cheng

  • Chin-Chung Shu

  • Hao-Chien Wang

  • February 14, 2026

  • 0 min

Share

Evaluation of Muscle Mass from Chest CT versus Body Mass Index in Bronchiectasis

Overview

This study evaluates the correlation between L1 muscle index (L1MI) and clinical outcomes in bronchiectasis patients, comparing it to traditional BMI assessments. Findings suggest that L1MI may provide more relevant insights into muscle mass and disease severity than BMI alone.

Background

Bronchiectasis is a chronic respiratory condition that significantly impacts patients' quality of life and requires effective management strategies. Nutritional status, particularly muscle mass, plays a critical role in disease outcomes, yet traditional metrics like BMI may not adequately reflect muscle health. This study aims to explore the utility of CT-derived muscle mass measurements in assessing bronchiectasis severity and outcomes.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

  • L1MI is proposed as a more accurate measure of muscle mass in bronchiectasis patients compared to BMI.
  • Low BMI is associated with increased mortality risk in bronchiectasis, as indicated by the Bronchiectasis Severity Index.
  • CT-derived muscle mass assessments correlate with exercise capacity and disease severity in chronic respiratory conditions.
  • Chest CT can provide valuable information on muscle status, aiding in the management of bronchiectasis.
  • Current guidelines emphasize the importance of addressing low body weight and malnutrition in bronchiectasis management.

Clinical Implications

Clinicians should consider incorporating L1MI assessments from chest CT into routine evaluations of bronchiectasis patients to better understand their muscle health and potential risks. Addressing nutritional status and muscle mass may improve management strategies and patient outcomes.

Conclusion

The study highlights the potential of L1MI as a superior metric for assessing muscle mass in bronchiectasis, suggesting that it could enhance the understanding of disease severity and inform clinical management.

References

  1. European Respiratory Society Clinical Practice Guideline for the Management of Adult Bronchiectasis, 2025 -- Guidelines on bronchiectasis management
  2. European Radiology, 2024 -- Assessment of Muscle Fat Fraction via Dual-Energy CT
  3. Obesity Surgery, 2020 -- Assessing Muscle Mass and Strength in Individuals with Obesity
  4. Updates in Surgery, 2020 -- Evaluation of Skeletal Muscle Mass via Magnetic Resonance Enterography
  5. Pectoralis Muscle Area as a Predictor of Mortality in Patients Hospitalized with Bronchiectasis Exacerbation, 2023 -- Study on muscle area and mortality
  6. Blood Cancer Journal — Body Composition Analysis in Patients with Recently Diagnosed Multiple Myeloma
  7. European Respiratory Society Clinical Practice Guideline for the Management of Adult Bronchiectasis
  8. https://bmcpulmmed.biomedcentral.com/counter/pdf/10.1186/s12890-025-03927-z.pdf
  9. Pectoralis Muscle Area as a Predictor of Mortality in Patients Hospitalized with Bronchiectasis Exacerbation | Respiration | Karger Publishers

Original Source(s)

Related Content